Bausch + Lomb Corporation (BLCO – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on May 17.

Bausch + Lomb's CEO, the veteran Pharma dealmaker Brent Saunders, has praised the performance of the existing business and ...

Bausch + Lomb has received seven reports of growths in the product's containers, though there have been no reports of illness ...

While CPSC and Bausch + Lomb said in the recall that those with ... had been reported by the time of the recall. CPSC said the products were sold at "PetSmart, Walmart, and other stores nationwide ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

Net loss attributable to Bausch + Lomb Corporation for the first quarter ... partially offset by an investment in launch products including MIEBO and XIIDRA. Foreign exchange revenue headwinds ...

over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and commercial footprint ...